Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Sep. 28, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net loss	$ (2,280,000)	$ (236,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation	395,000	529,000
Amortization	583,000	684,000
Stock based compensation expense	78,000	245,000
Change in fair value of warrant liability	(13,000)	(634,000)
Changes in operating assets and liabilities:
Accounts receivable - net	(329,000)	(916,000)
Inventories	(112,000)	108,000
Prepaid expenses and other assets	(237,000)	(28,000)
Accounts payable and accrued expenses	686,000	(274,000)
Net cash used in operating activities	(1,229,000)	(522,000)
Cash flows from investing activities:
Capital expenditures	(198,000)	(406,000)
Change in restricted cash		500,000
Patent expenditures	(69,000)	(102,000)
Net cash used in investing activities	(267,000)	(8,000)
Cash flows from financing activities:
Proceeds on bank term loan		1,000,000
Payments on bank term loan	(167,000)	(688,000)
Net proceeds on bank line of credit	300,000
Payments on MEDC/MSF term loan	(262,000)	(253,000)
Payments on related parties debt		(450,000)
Proceeds from exercise of stock options		25,000
Net cash used in financing activities	(129,000)	(366,000)
Net decrease in cash and cash equivalents	(1,625,000)	(896,000)
Cash and cash equivalents at beginning of period	3,249,000	4,744,000
Cash and cash equivalents at end of period	1,624,000	3,848,000
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 58,000	$ 98,000